NCT05032040: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
- State
- Under way
- Phase
- Phase 2
- People
- 170 planned
- Started
- 21 Jul 2022
- Primary completion
- 15 Oct 2025
- Arms
- vudalimab
- Results
- None posted
- 2 Sep 2021: Trial registered
- 21 Jul 2022: Trial started